CN102552177B - Freeze-dried recombinant human brain natriuretic peptide (rhBNP) preparation and preparation method thereof - Google Patents
Freeze-dried recombinant human brain natriuretic peptide (rhBNP) preparation and preparation method thereof Download PDFInfo
- Publication number
- CN102552177B CN102552177B CN 201110453432 CN201110453432A CN102552177B CN 102552177 B CN102552177 B CN 102552177B CN 201110453432 CN201110453432 CN 201110453432 CN 201110453432 A CN201110453432 A CN 201110453432A CN 102552177 B CN102552177 B CN 102552177B
- Authority
- CN
- China
- Prior art keywords
- rhbnp
- preparation
- nacl
- sample
- stability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 101500026735 Homo sapiens Brain natriuretic peptide 32 Proteins 0.000 title abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- 239000007853 buffer solution Substances 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 56
- 239000011780 sodium chloride Substances 0.000 claims description 27
- 238000009472 formulation Methods 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000008215 water for injection Substances 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000005457 optimization Methods 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 108091006629 SLC13A2 Proteins 0.000 abstract 1
- 241000411851 herbal medicine Species 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 34
- 238000012360 testing method Methods 0.000 description 31
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 30
- 102000008100 Human Serum Albumin Human genes 0.000 description 22
- 108091006905 Human Serum Albumin Proteins 0.000 description 22
- 238000000034 method Methods 0.000 description 20
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 11
- 229930195725 Mannitol Natural products 0.000 description 11
- 239000000594 mannitol Substances 0.000 description 11
- 235000010355 mannitol Nutrition 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 239000004471 Glycine Substances 0.000 description 9
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 9
- 229940027278 hetastarch Drugs 0.000 description 9
- 229960001802 phenylephrine Drugs 0.000 description 9
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 9
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 7
- 238000011835 investigation Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 235000017281 sodium acetate Nutrition 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 102000013138 Drug Receptors Human genes 0.000 description 1
- 108010065556 Drug Receptors Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 102000027424 natriuretic peptide receptors Human genes 0.000 description 1
- 108091008599 natriuretic peptide receptors Proteins 0.000 description 1
- 230000010494 opalescence Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a freeze-dried recombinant human brain natriuretic peptide (rhBNP) preparation. The preparation is prepared from the following Chinese herbal medicines and auxiliary materials in part by weight: 0.5 part of rhBNP, 0.2 to 20 parts of buffer solution system, 1 to 20 parts of excipient and 1 to 20 parts of NaC1. The invention also discloses a preparation method for the freeze-dried rhBNP preparation. By optimization of the auxiliary materials, rhBNP has high stability, and effectiveness and safety of medicines are ensured.
Description
Technical field
The present invention relates to lyophilized formulations of rhBNP and preparation method thereof, belong to drug world.
Background technology
RhBNP (rhBNP) is succeeded in developing by the U.S., and be used for the treatment of clinically the medicine of new generation of congestive heart failure, mechanism of its treatment heart failure be it to a certain extent can the antagonism epinephrine, the activity of Re-A-A element and endothelin system, relax vascular smooth muscle and expand the peripheral artery vein blood vessel, increase the drainage of sodium and sharp sodium, diuresis, alleviate the front and back load of heart, be of value to the alleviation of the heart failure state of an illness.
The lyophilizing recombinant human brain natriuretic peptide of domestic clinical practice, trade name are newly lived plain, every 0.5mg.For acute heart failure patient's treatment, detailed directions: the plain 0.5mg that newly lives is dissolved in 100ml liquid, gives loading dose 1.5 μ g/kg, intravenous injection, and the time of injecting must not be less than 90 seconds, the remaining vena axillaris 0.01 μ g (kgmin) that instils
-1, persistent instillation, SM 48～72 hours.For example, be the patient of 60kg for body weight, will extract the quiet notes of 18～20ml in the 100ml liquid, remaining liquid 7～8ml/h continuous intravenous infusion.For the treatment of chronic heart failure, detailed directions is: give (0.0075～0.01) μ g (kgmin)
-1Intravenous drip, 1～2 outpatient service vein treatment weekly, be 12 weeks the course for the treatment of.Yet, because rhBNP is polypeptide drug, it may stand the chemical degradation of Various Complex and physical change under the environment and inactivation in vivo and in vitro, therefore, the method that research improves the stability of this pharmaceutical preparation just seems particularly necessary, at present also not about improving the pertinent literature report of the plain lyophilized formulations stability of new work.
Summary of the invention
Technical scheme of the present invention has provided a kind of rhBNP lyophilized formulations of good stability.This bright preparation method that this lyophilized formulations also is provided.
The invention provides a kind of rhBNP lyophilized formulations, it is to be prepared from by the crude drug of following weight proportion and adjuvant:
0.5 part of rhBNP, buffer solution system 0.2-20 part, excipient 1-20 part, NaCl 1-20 part.
Wherein, described buffering liquid is phosphate, citric acid and acetate; Be preferably phosphate or citric acid.
Wherein, described buffering liquid is phosphate.
Wherein, described excipient is human serum albumin, mannitol, glycine, hetastarch; Be preferably human serum albumin or mannitol.
Wherein, described excipient is the human serum albumin.
RhBNP lyophilized formulations of the present invention is that crude drug and the adjuvant by following weight proportion is prepared from:
0.5 part of rhBNP, human serum albumin 1-20 part, Na
2HPO
40.1-10 part, NaH
2PO
40.1-10 part, NaCl 1-20 part.
Further preferably, it is that crude drug and adjuvant by following weight proportion is prepared from:
0.5 part of rhBNP, 10 parts of human serum albumins, Na
2HPO
41.73 part, NaH
2PO
40.93 part, 9 parts of NaCl.
The present invention also provides the preparation method of this rhBNP lyophilized formulations, and it comprises the steps:
(1) gets rhBNP, buffer solution system, excipient, the NaCl of recipe quantity, with water for injection dissolving, solution for standby; Or
(2) get buffer solution system, excipient, the NaCl of recipe quantity, be dissolved in the solution of the rhBNP that contains recipe quantity the gained solution for standby;
(3) behind the solution impurity removal and purification with step (1) or (2) gained, with the refined liquid packing, lyophilization gets product.
Preferred by to adjuvant of the present invention so that rhBNP has good stability, guaranteed effectiveness and the safety of medicine.
The specific embodiment of form is described in further detail foregoing of the present invention again by the following examples.But should not be understood as limiting the scope of the invention, all based on above-mentioned technological thought, the modification, replacement, the change that utilize ordinary skill knowledge and customary means to make all belong to scope of the present invention.
Description of drawings
Fig. 1 example schematic
The specific embodiment
The selection of embodiment 1 rhBNP bottling dosage
The bibliographical information of the clinical trial that external rhBNP is relevant: external clinical present recommended dose is that intravenous drip is 0.015ug/kg.min and 0.03ug/kg.min, continuous drip 6 hours, be 80kg by American-European average man body weight, therefore every dosage specification should be 432ug and 864ug.We, tentatively determine with 0.015 μ g/kg.min as dosage in conjunction with the document of abroad having delivered by the pharmacological effect test to animal; By Chinese's average weight in 60kg, continuously quiet 6 hours, then every dosage should be 324 μ g, so the bottling amount is increased to 500 μ g/ dosage.
Embodiment 2 rhBNP 0.5mg
Na
2HPO
4 1.73mg
NaH
2PO
4 0.93mg
Human serum albumin 10mg
NaCl9mg
Method for making: after the dissolving, add proper amount of active carbon, mixing, after suitably leaving standstill, through coarse filtration, fine straining, get refined liquid, prop up packing by 1ml/ after, lid is rolled in lyophilization, gets product, and contains rhBNP 500RU (0.5mg) in every finished product.
Embodiment 3 rhBNP 0.5mg
Na
2HPO
4 1.73mg
NaH
2PO
4 0.93mg
Mannitol 8mg
NaCl 9mg
Method for making is with embodiment 2
Embodiment 4 rhBNP 0.5mg
Na
2HPO
4 1.73mg
NaH
2PO
4 0.93mg
Glycine 6mg
NaCl 9mg
Method for making is with embodiment 2
Embodiment 5 rhBNP 0.5mg
Na
2HPO
4 1.73mg
NaH
2PO
4 0.93mg
Hetastarch 6mg
NaCl 9mg
Method for making is with embodiment 2
Embodiment 6 rhBNP 0.5mg
Sodium citrate 5.9mg
Citric acid 0.11mg
Human serum albumin 10mg
NaCl 9mg
Method for making is with embodiment 2
Embodiment 7 rhBNP 0.5mg
Sodium citrate 5.9mg
Citric acid 0.11mg
Mannitol 8mg
NaCl 9mg
Method for making is with embodiment 2
Embodiment 8 rhBNP 0.5mg
Sodium citrate 5.9mg
Citric acid 0.11mg
Glycine 6mg
NaCl 9mg
Method for making is with embodiment 2
Embodiment 9 rhBNP 0.5mg
Sodium citrate 5.9mg
Citric acid 0.11mg
Hetastarch 6mg
NaCl 9mg
Method for making is with embodiment 2
Embodiment 10 rhBNP 0.5mg
Sodium acetate 1.64mg
Acetic acid 0.002mg
Human serum albumin 10mg
NaCl 9mg
Method for making is with embodiment 2
Embodiment 11 rhBNP 0.5mg
Sodium acetate 1.64mg
Acetic acid 0.002mg
Mannitol 8mg
NaCl 9mg
Method for making is with embodiment 2
Embodiment 12 rhBNP 0.5mg
Sodium acetate 1.64mg
Acetic acid 0.002mg
Glycine 6mg
NaCl 9mg
Method for making is with embodiment 2
Embodiment 13 rhBNP 0.5mg
Sodium acetate 1.64mg
Acetic acid 0.002mg
Hetastarch 6mg
NaCl 9mg
Method for making is with embodiment 2
Below be long-term stable experiment and the activity test of prescription screening test and preparation.
Test example 1 rhBNP lyophilized formulations prescription optimization test
One. test method:
The preparation prescription optimization test is mainly determined by the stability that detects rhBNP under the different pharmaceutical formulation conditions, is specially with the RP-HPLC method content of the rhBNP in the finished product is measured.
Chromatographic column: Source 5RPC 4.6/150 prepacked column (Pharmacia Biotech)
Instrument: AKTA explorer100
The RP-HPLC condition is: mobile phase A is the water that contains 0.1%TFA, 5%Acetonitrile; Mobile phase B is the Acetonitrile that contains 0.1%TFA, 10% water; Gradient is: 0% → 20%B, 2CV, and 20% → 30%B, 3CV, 30% → 80%B, 1CV, applied sample amount are 500 μ l, flow velocity is 0.5ml/min, detects wavelength 215nm.
Two. the pharmaceutical formulation adjuvant
Table 1: pharmaceutical formulation adjuvant
| Adjuvant | Manufacturer |
| Na 2HPO 4 | The Chengdu chemical reagent factory |
| NaH 2PO 4 | The Chengdu chemical reagent factory |
| Citric acid | The Chengdu chemical reagent factory |
| Sodium citrate | The Chengdu chemical reagent factory |
| Acetic acid | The Chengdu chemical reagent factory |
| Sodium acetate | The Chengdu chemical reagent factory |
| NaCl | The Chengdu chemical reagent factory |
| Mannitol | The Chengdu chemical reagent factory |
| Glycine | The Chengdu chemical reagent factory |
| Hetastarch | The Chengdu chemical reagent factory |
| The human serum albumin | Chengdu Inst. of Biological Products |
Three. the preparation prescription optimization test
Biological product will keep its biological activity as much as possible, and dosage form must be stablized, and is easy and simple to handle, is easy to repetition, and the management that can strictly regulate.Lyophilized formulations is a kind of dosage form that present biological product extensively adopt.
1. the selection of dosage
The bibliographical information of the clinical trial that external rhBNP is relevant: external clinical present recommended dose is that intravenous drip is 0.015ug/kg.min and 0.03ug/kg.min, continuous drip 6 hours, be 80kg by American-European average man body weight, therefore every dosage specification should be 432ug and 864ug.We, tentatively determine with 0.015 μ g/kg.min as dosage in conjunction with the document of abroad having delivered by the pharmacological effect test to animal; By Chinese's average weight in 60kg, continuously quiet 6 hours, then every dosage should be 324 μ g, considers the report that there is no at present Chinese's clinical trial, so the bottling amount is increased to 500 μ g/ dosage.
2. the selection of buffer system
500 μ grhBNP are dissolved in the 1ml buffer, and buffer system adopts respectively phosphate, citric acid and acetate, and concentration does not wait from 5mM-100mM, PH remains between the 5-8, and temperature is 2-8 ℃, and the time is one month, investigate the stability of sample, result of the test following (μ g):
Table 2: buffer system and PH are on the impact (concentration) of rhBNP stability
| Buffer PH | 5 | 5.5 | 6 | 6.5 | 7 | 7.5 | 8 |
| Phosphate | 387 | 396 | 413 | 422 | 468 | 486 | 416 |
| Citric acid | 346 | 398 | 394 | 415 | 435 | 457 | 392 |
| Acetate | 322 | 372 | 388 | 398 | 416 | 421 | 386 |
It is as follows to be converted into percentage result:
Table 3: buffer system and PH are on the impact (percentage ratio) of rhBNP stability
| Buffer PH | 5 | 5.5 | 6 | 6.5 | 7 | 7.5 | 8 |
| Phosphate | 77.4 | 79.2 | 82.6 | 84.4 | 93.6 | 97.2 | 83.2 |
| Citric acid | 69.2 | 79.6 | 78.8 | 83.0 | 87.0 | 91.4 | 78.4 |
| Acetate | 64.4 | 74.4 | 77.6 | 79.6 | 83.2 | 84.2 | 77.2 |
The result shows that buffer system adopts phosphate 20mM, PH7.5 (corresponding Na
2HPO
41.7mg, NaH
2PO
40.93mg), sample stability is best.
3. the selection of excipient
500 μ grhBNP are dissolved in phosphate buffer (20mM, PH7.5), difference end user serum albumin, mannitol, glycine, hetastarch excipient, and temperature is 2-8 ℃, the time is one month, investigates the stability of sample.
(1) human serum albumin
Table 4: the different amounts human serum albumin is on the impact of rhBNP stability
| The human serum albumin | 0 | 2.5mg | 5mg | 10mg | 20mg | 40mg |
| RhBNP content | 481 | 489 | 497 | 499 | 493 | 486 |
| Percentage ratio | 96.2 | 97.8 | 99.4 | 99.8 | 98.6 | 97.2 |
(2) mannitol
Table 5: different amounts mannitol is on the impact of rhBNP stability
| Mannitol | 0 | 2mg | 4mg | 8mg | 16mg | 32mg |
| RhBNP content | 483 | 487 | 497 | 498 | 489 | 487 |
| Percentage ratio | 96.6 | 97.4 | 99.4 | 99.6 | 97.8 | 97.4 |
(3) glycine
Table 6: the different amounts glycine is on the impact of rhBNP stability
| Glycine | 0 | 2mg | 4mg | 8mg | 16mg | 32mg |
| RhBNP content | 482 | 486 | 493 | 489 | 487 | 487 |
| Percentage ratio | 96.4 | 97.2 | 98.6 | 97.8 | 97.4 | 97.4 |
(4) hetastarch
Table 7: the different amounts hetastarch is on the impact of rhBNP stability
| Hetastarch | 0 | 2mg | 4mg | 8mg | 16mg | 32mg |
| RhBNP content | 483 | 487 | 494 | 491 | 488 | 486 |
| Percentage ratio | 96.6 | 97.4 | 98.8 | 98.2 | 97.6 | 97.2 |
The result shows human serum albumin or mannitol better effects if, and the human serum albumin has better effect.In the biological product manufacture process, adding the human serum albumin has good protective effect to the stability of albumen or polypeptide usually, thereby is often used as excipient.
Select the human serum albumin as excipient on the basis of test in front, and select the human serum albumin of 1% and 0.5% concentration under different temperatures, to carry out the study on the stability of sample.The result shows that the human serum albumin of two kinds of concentration all has good protective effect to rhBNP, but it is better to add 1% human serum albumin (being that human albumin's consumption is 10mg) molding effect.Therefore select 1% human serum albumin as formulation concentrations.
Table 8: variable concentrations human serum albumin condition of different temperatures is on the impact of rhBNP stability
The selection of NaCl
In the manufacturing process, contain NaCl in the rhBNP solution that obtains, consider that human body needs 150mM NaCl to keep etc. and oozes, so contain NaCl in the goods.And in lyophilizing, contain the goods of 150mM NaCl under the condition of identical lyophilizing, its moisture is lower, so more be conducive to the preservation of rhBNP lyophilized formulations.
The test of test example 2 lyophilized formulations prescription screenings
The difference of lyophilized formulations on outward appearance, dissolution time, clarity and stability that different formulations makes investigated in the prescription screening test.Outward appearance should be white shelly loosening body, and dissolubility will be got well (planted agent was dissolved fully in 5 minutes), should be clear liquid after the dissolving, and especially the stability of rhBNP will be got well.
The stability of rhBNP adopts the RP-HPLC method that the content of the rhBNP in the lyophilized formulations is measured to reflect.Concrete detection method is as follows:
Chromatographic column: Source 5RPC 4.6/150 prepacked column (Pharmacia Biotech)
Instrument: AKTA explorer100
The RP-HPLC condition is: mobile phase A is the water that contains 0.1%TFA, 5%Acetonitrile; Mobile phase B is the Acetonitrile that contains 0.1%TFA, 10% water; Gradient is: 0% → 20%B, 2CV, and 20% → 30%B, 3CV, 30% → 80%B, 1CV, applied sample amount are 500 l, flow velocity is 0.5ml/min, detects wavelength 215nm.
By the lyophilized formulations that above-mentioned prescription makes, temperature is 2-8 ℃, and the time is one month, comes the stability of judgement sample by the content of measuring rhBNP.
Lyophilized formulations prescription screening result of the test is as follows:
The test of table 9 lyophilized formulations prescription screening
Result of the test shows, adopts embodiment 2 (rhBNP 0.5mg, Na
2HPO
41.73mg, NaH
2PO
40.93mg, human serum albumin 10mg, NaCl 9mg) described preparation prescription the lyophilized formulations dissolubility, clarity, the optimal stability that obtain.
Long-term stable experiment and the activity test of test example 3 lyophilized formulations prescription
Investigate long-time stability and the activity of embodiment 2 described pharmaceutical formulations.The quality of the pharmaceutical preparations requires such as following table:
Table 10 formulation samples prescription
| Index | Quality of the pharmaceutical preparations requirement |
| Outward appearance | Should be white shelly loosening body. |
| Dissolution time | With the water for injection dissolving, the planted agent was dissolved fully in 5 minutes under the room temperature. |
| Clarity | Little clear liquid with opalescence is not answered precipitation muddy, that contain foreign body or cannot not shake loosely. |
| PH value | 6.5～8.0 |
| Active | 500RU |
| Moisture | ≤ 3.0% (g/g) |
Content of the test:
1.2～8 ℃ of investigations that keep sample: this product is placed 2～8 ℃ of refrigerators, be set in respectively and March, June, JIUYUE, December, 18 months, 24 months, 30 months, 36 months philosophies measure above index.
2. the room temperature investigation that keeps sample: this product is placed 25 ℃ of calorstats, be set in respectively and March, June, JIUYUE, December, 18 months, 24 months, 30 months philosophies measure above index.
The investigation 3.37 ℃ keep sample: this product is placed 37 ℃ of calorstats, be set in respectively and March, June, JIUYUE, December, 18 months, 24 months, 30 months philosophies measure above index.
3. biological activity test assay method (tremulous pulse bar method)
Material: the rhBNP sample, specification: 0.5mg/ props up,
Phenylephrine, Shanghai Hefeng Pharmaceutical Co., Ltd. produces, lot number: 981101
RhBNP work is with reference to product, and specification is that 0.1mg/ props up, and activity is 100U, is provided by this laboratory.
Principle: at first utilize Phenylephrine and its receptors bind on blood vessel, produce the contracting vascular effect, the resting tension of blood vessel is improved, and stable maintenance is at certain level, then utilize rhBNP to be combined with its natriuretic peptide receptor on blood vessel, generation by the variation of antiotasis, is measured the biological activity of rhBNP to the vasorelaxation of Rabbit Thoracic Aortic bar.
3.1 the compound method of solution:
The preparation of tissue fluid: the prescription of tyrode ' s liquid (with 1 liter of solution note):
NaCl 8g；KCl 0.2g；MgSO
4.7H2O 0.26g；NaH
2PO
4 0.065g；NaHCO
3 1g；Glucose 1g；CaCl
2 0.2g
First will be except CaCl
2Other component in addition adds in the 600ml distilled water to fully dissolving, again with CaCl
2Add in the 40ml distilled water to fully dissolving, again with CaCl
2Solution slowly adds when stirring in the 600ml solution, and is at last that the solution dilution that mixes is for subsequent use to 1000ml.
With normal saline the concentration of Phenylephrine is formulated as 1.25 * 10
-2Mg/ml;
Respectively rhBNP work is dissolved in the 1ml normal saline with reference to product and testing sample first, and then is diluted to 0.1mg/ml concentration, press again 1: 10 dilution proportion standard sample and testing sample, and be numbered with manage number as follows:
The pipe number: No.1 No.2 No.3
RhBNP work is with reference to product---→ 0.1mg/ml---→ 0.01mg/ml---→ 0.001mg/ml
RhBNP testing sample---→ 0.1mg/ml---→ 0.01mg/ml---→ 0.001mg/ml
3.2 the preparation of tremulous pulse bar
Get one of 1.5-2.0kg new zealand rabbit, with pentobarbital sodium anesthesia, then put to death with dislocation method, get branches of descending thoracic aorta.The artery bar is cut into long, the wide tremulous pulse spiral bar of 2.5mm about 1.5cm, and hang in the Magnus' bath that contains 20ml tyrode's solution (37 ℃), logical oxygen, pH value remains on 7.4, blood vessel is added the 1g preload, stablized 2 hours, changed 1 time tyrode's solution therebetween in per 20 minutes, the monitor chart drive speed is adjusted to 2.5mm/min, sensitivity * 0.02.The tension variation of record blood vessel.
After baseline stability, the 0.05ml Phenylephrine that adding prepares is in Magnus' bath, and making its final concentration in Magnus' bath is 1.56 * 10
-4Mg/ml, curve rise to peak and stable after, begin to add the rhBNP standard sample by the cumulative concentration dose regimen, and the record tension variation.
3.3 accumulation dosage regimen: following steps, from work with reference to No. three of QC pipe, add respectively 6.25,6.25,12.5,25,50 in the Magnus' bath at every turn, 100ul, and then get second and manage, add respectively 20,40 at every turn, 80ul, get again the first pipe, add respectively 16,32, the 64ul sample at every turn.Each add sample after, wait until that tension curve is reduced to steady position after, enter into again next step dosing program, until tension curve is near baseline.
Step is as follows:
3.4 after finishing above-mentioned administration, eluting was also stablized 1 hour, changed tyrode's solution 1 time in per 20 minutes therebetween, after baseline stability, added Phenylephrine solution that 0.05ml prepares in Magnus' bath again, then its final concentration in Magnus' bath is 1.56 * 10
-4Mg/ml, curve rise to peak and stable after, begin to add the rhBNP testing sample by the cumulative concentration dose regimen, the accumulation medication with reference to product, and records tension variation with work.
3.5 the record of data and processing
The record format of according to the form below, data are recorded and process, final concentration value after wherein the Conc. representative sample adds in the Magnus' bath, LogC represents the common logarithm value of this final concentration, A representative in each adding work with reference to product and the tension force amplitude that behind tension stability, begins from baseline, OA represents the tension variation value that each adding work begins with reference to product and the stable tension platform from adding rising that Phenylephrine produces behind tension stability, OA% represents OA with respect to the relative value of the tension force of the stable tension platform that adds rising that Phenylephrine produces, B representative is in each testing sample and tension force amplitude that begins from baseline behind tension stability of adding, the tension variation value that OB representative each adding testing sample and the stable tension platform from adding rising that Phenylephrine produces behind tension stability begin, OB% represents OB with respect to the relative value of the tension force amplitude of the stable tension platform that adds rising that Phenylephrine produces.
Example schematic is seen Fig. 1: i.e. OA=K-A, OB=K-B, OA%=(K-A)/K, OB%=(K-B)/K
OA% and OB% have represented respectively the work of rhBNP with reference to the reaction percentage rate of product and vasodilator effect that testing sample produces, respectively LogC value and OA%, the input of OB% value in the software of the drug receptor Analytical Computer Program establishment that " Shanghai the first medical college journal " the 12nd volume the 5th phase 347-349 page or leaf is delivered, are obtained ED50 separately with reference to the Xu Duan full professor.
3.6 the calculating of testing sample activity
Active computing formula is:
Sample activity=standard substance activity * (standard substance ED
50* diluted sample multiple)/(sample ED
50* standard substance extension rate)
The result is as follows for the formulation samples stability test:
4～8 ℃ of investigation specification: 500RU that keep sample of table 11 recombinant human brain natriuretic peptide lyophilized injectable powder
The result: recombinant human brain natriuretic peptide lyophilized injectable powder (specification: 500RU/ props up) sample is at 2～8 ℃ of reserved sample observings, and sampling detects indices at the appointed time, and is relatively front, almost unchanged with test, activity stabilized (more than 97%), indices meets the requirements.
Table 12 recombinant human brain natriuretic peptide lyophilized injectable powder room temperature investigation specification: the 500RU that keeps sample
The result: recombinant human brain natriuretic peptide lyophilized injectable powder (specification: 500RU/ props up) sample is at the room temperature reserved sample observing, and sampling detects indices at the appointed time, and is relatively front, almost unchanged with test, activity stabilized (more than 93%), indices meets the requirements.
37 ℃ of investigation specification: 500RU that keep sample of table 13 recombinant human brain natriuretic peptide lyophilized injectable powder
The result: recombinant human brain natriuretic peptide lyophilized injectable powder (specification: 500RU/ props up) sample is at 37 ℃ of reserved sample observings, and sampling detects indices at the appointed time, and is relatively front, almost unchanged with test, activity stabilized (more than 85%), indices meet clinical front prescription.
The rhBNP lyophilized formulations was preserved 12 months under higher temperature, and its pharmaceutically active still can reach more than 85%, under nearly room temperature, preserved 12 months, its pharmaceutically active remains on more than 93%, stored refrigerated 12 months, and its pharmaceutically active remains on more than 97%.Preferred by to pharmaceutical formulation so that rhBNP has good stability, guaranteed effectiveness and the safety of medicine.
Claims (1)
1. rhBNP lyophilized formulations, it is characterized in that: it is to be prepared from by the crude drug of following weight proportion and adjuvant:
0.5 part of rhBNP, 10 parts of human serum albumins, Na
2HPO
41.73 part, NaH
2PO
40.93 part, 9 parts of NaCl.
2, the preparation method of rhBNP lyophilized formulations claimed in claim 1, it is characterized in that: it comprises the steps:
(1) gets rhBNP, buffer solution system, excipient, the NaCl of recipe quantity, with water for injection dissolving, solution for standby; Or
(2) get buffer solution system, excipient, the NaCl of recipe quantity, be dissolved in the solution of the rhBNP that contains recipe quantity the gained solution for standby;
(3) behind the solution impurity removal and purification with step (1) or (2) gained, with the refined liquid packing, lyophilization gets product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110453432 CN102552177B (en) | 2010-12-30 | 2011-12-30 | Freeze-dried recombinant human brain natriuretic peptide (rhBNP) preparation and preparation method thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010614247 | 2010-12-30 | ||
| CN201010614247.4 | 2010-12-30 | ||
| CN 201110453432 CN102552177B (en) | 2010-12-30 | 2011-12-30 | Freeze-dried recombinant human brain natriuretic peptide (rhBNP) preparation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102552177A CN102552177A (en) | 2012-07-11 |
| CN102552177B true CN102552177B (en) | 2013-04-10 |
Family
ID=46399645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110453432 Active CN102552177B (en) | 2010-12-30 | 2011-12-30 | Freeze-dried recombinant human brain natriuretic peptide (rhBNP) preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102552177B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103990115B (en) * | 2014-05-09 | 2016-06-15 | 深圳翰宇药业股份有限公司 | A kind of Nesiritide pharmaceutical composition and preparation method thereof, preparation |
| CN104825403B (en) * | 2015-04-30 | 2019-06-04 | 上海景泽生物技术有限公司 | A kind of freeze-dried B-type natriuretic peptide preparation and preparation method thereof |
| CN104861075B (en) * | 2015-05-08 | 2018-06-08 | 成都金凯生物技术有限公司 | A kind of long-acting recombinant human brain natriuretic peptide fusion protein and preparation method thereof and purposes |
| TWI773649B (en) | 2015-07-30 | 2022-08-11 | 美商拜奧馬林製藥公司 | Use of c-type natriuretic peptide variants to treat skeletal dysplasia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060008415A1 (en) * | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
| EP2234603A1 (en) * | 2007-12-19 | 2010-10-06 | EKR Therapeutics, Inc. | Room temperature stable, lyophilized natriuretic peptide formulations |
| JP4568334B2 (en) * | 2008-01-29 | 2010-10-27 | 三洋化成工業株式会社 | Antigen-containing aqueous solution |
-
2011
- 2011-12-30 CN CN 201110453432 patent/CN102552177B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102552177A (en) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kinnunen et al. | A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components | |
| Stohlawetz et al. | Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans | |
| Misra et al. | A Phase Ib open label, randomized, safety study of SANGUINATE™ in patients with sickle cell anemia | |
| US10925931B2 (en) | Rapid-acting insulin compositions | |
| Kok-Yong et al. | Drug distribution and drug elimination | |
| McNiff et al. | Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects | |
| CN102552177B (en) | Freeze-dried recombinant human brain natriuretic peptide (rhBNP) preparation and preparation method thereof | |
| US20160367640A1 (en) | Rapid-acting insulin compositions | |
| JP2016532698A (en) | Stable aqueous parenteral pharmaceutical composition of insulinotropic peptide | |
| Gehr et al. | The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency | |
| Bolli et al. | Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes | |
| Teirstein et al. | Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization | |
| Gejl et al. | Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain | |
| Rasmussen et al. | Insulin aspart pharmacokinetics: an assessment of its variability and underlying mechanisms | |
| Lehmann et al. | Bioequivalence Comparison between Hydroxyethyl Starch 130/0.42/6: 1 and Hydroxyethyl Starch 130/0.4/9: 1 | |
| Yokel et al. | Aluminum distribution into brain and liver of rats and rabbits following intravenous aluminum lactate or citrate: A microdialysis study | |
| Sparreboom et al. | The (ir) relevance of plasma protein binding of anticancer drugs | |
| Ovbude et al. | High-Performance affinity chromatographic studies of repaglinide and nateglinide interactions with normal and glyoxal-or methylglyoxal-modified human albumin serum | |
| Yu et al. | Quantitative analysis of insulin in total parenteral nutrition bag in Taiwan | |
| Plock et al. | Successful management of discovered pH dependence in vancomycin recovery studies: novel HPLC method for microdialysis and plasma samples | |
| Verbeeck et al. | Disposition of furosemide in functionally hepatectomized dogs. | |
| Mendel et al. | Thyroxine uptake by perfused rat liver. No evidence for facilitation by five different thyroxine-binding proteins. | |
| Ptachcinski et al. | Stability and availability of cyclosporine in 5% dextrose injection or 0.9% sodium chloride injection | |
| CN102512360B (en) | Torasemide pharmaceutical composition with stabilization and safety for injection | |
| Kongmalai et al. | The Effect of high temperature on the stability of basal insulin in a pen: a randomized controlled, crossover, equivalence trial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170816 Address after: 850000 Beijing Middle Road, Tibet, No. 93 Middle Road, Lhasa Patentee after: Nuodikang Pharmaceutical Industry Co., Ltd., Tibet Address before: 610023 Jinjiang Industrial Development Zone, Sichuan, Chengdu Patentee before: Chengdu Nuodikang Biological Pharmaceutical Co., Ltd. |
|
| TR01 | Transfer of patent right |